The groundbreaking success of Viagra undeniably revolutionized the drug landscape, but investing in companies heavily reliant on off-patent versions presents a challenging picture. While early profits were substantial, the end of patents and the rise of cheaper alternatives have eroded sales. Therefore, a thorough assessment of ongoing financial pe